Emixustat: Completed Phase IIb/III enrollment

Acucela completed enrollment of 508 patients in the double-blind, placebo-controlled Phase IIb/III SEATTLE trial evaluating 2.5, 5 and 10 mg oral emixustat once daily for 24 months. The product has Fa...